4/17
06:42 am
nvs
Novartis AG (NYSE: NVS) was upgraded by analysts at BNP Paribas to a "strong-buy" rating.
Low
Report
Novartis AG (NYSE: NVS) was upgraded by analysts at BNP Paribas to a "strong-buy" rating.
4/16
04:28 am
nvs
Thyroid Eye Disease Treatment Market Forecast to Reach $11.81 Billion by 2031 | Emerging Economies Expand Access to Thyroid Eye Disease Diagnoses and Therapies [Yahoo! Finance]
Low
Report
Thyroid Eye Disease Treatment Market Forecast to Reach $11.81 Billion by 2031 | Emerging Economies Expand Access to Thyroid Eye Disease Diagnoses and Therapies [Yahoo! Finance]
4/14
08:35 am
nvs
Liver Fluke Treatment Market Growth Drivers, Industry Trends and Forecasts 2025-2034 | Global Liver Fluke Treatment Market Grows at 4.8% CAGR Amid Rising Anthelmintic Drug Demand [Yahoo! Finance]
Low
Report
Liver Fluke Treatment Market Growth Drivers, Industry Trends and Forecasts 2025-2034 | Global Liver Fluke Treatment Market Grows at 4.8% CAGR Amid Rising Anthelmintic Drug Demand [Yahoo! Finance]
4/14
08:19 am
nvs
Saisei Ventures Launches Executive Fellows Program Aiming to Enhance Japan's Biotech Leadership Pipeline [Yahoo! Finance]
Low
Report
Saisei Ventures Launches Executive Fellows Program Aiming to Enhance Japan's Biotech Leadership Pipeline [Yahoo! Finance]
4/14
07:19 am
nvs
Bio-Thera Solutions Presents Clinical Data for multiple products at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
Low
Report
Bio-Thera Solutions Presents Clinical Data for multiple products at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
4/14
05:08 am
nvs
Novartis (NVS) Surges 4.0%: Is This an Indication of Further Gains? [Yahoo! Finance]
Low
Report
Novartis (NVS) Surges 4.0%: Is This an Indication of Further Gains? [Yahoo! Finance]
4/11
03:22 pm
nvs
NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat [Yahoo! Finance]
Low
Report
NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat [Yahoo! Finance]
4/10
02:29 pm
nvs
Novartis plans to invest $23 billion in US plants as Trump renews drug tariff threats [CNBC]
Low
Report
Novartis plans to invest $23 billion in US plants as Trump renews drug tariff threats [CNBC]
4/10
02:24 pm
nvs
Novartis plans to expand its US-based manufacturing and R&D footprint with a total investment of $23B over the next 5 years [Yahoo! Finance]
Low
Report
Novartis plans to expand its US-based manufacturing and R&D footprint with a total investment of $23B over the next 5 years [Yahoo! Finance]
4/10
09:02 am
nvs
Novartis leaves NC incentive as it lowers hiring target at Durham manufacturing site [Yahoo! Finance]
Low
Report
Novartis leaves NC incentive as it lowers hiring target at Durham manufacturing site [Yahoo! Finance]
4/7
07:30 pm
nvs
CareMed Has Been Selected as a National Specialty Pharmacy Partner for VANRAFIA™ (atrasentan) [Yahoo! Finance]
Low
Report
CareMed Has Been Selected as a National Specialty Pharmacy Partner for VANRAFIA™ (atrasentan) [Yahoo! Finance]
4/6
01:59 pm
nvs
Prostate cancer drug now available to more patients with aggressive form of disease [FOX News]
Low
Report
Prostate cancer drug now available to more patients with aggressive form of disease [FOX News]
4/3
04:26 pm
nvs
Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront [Yahoo! Finance]
Medium
Report
Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront [Yahoo! Finance]
4/2
08:29 pm
nvs
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
Low
Report
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
4/2
07:42 am
nvs
Novartis AG (VTX:NOVN) most popular amongst individual investors who own 53% of the shares, institutions hold 42% [Yahoo! Finance]
Low
Report
Novartis AG (VTX:NOVN) most popular amongst individual investors who own 53% of the shares, institutions hold 42% [Yahoo! Finance]
3/31
07:44 am
nvs
Isomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic [Yahoo! Finance]
Low
Report
Isomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic [Yahoo! Finance]
3/28
08:13 pm
nvs
Here's Why Novartis (NVS) is a Strong Value Stock [Yahoo! Finance]
Low
Report
Here's Why Novartis (NVS) is a Strong Value Stock [Yahoo! Finance]
3/28
08:13 pm
nvs
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer [Yahoo! Finance]
Low
Report
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer [Yahoo! Finance]
3/27
07:33 am
nvs
Pharmaceutical Industry Veteran, Ashish Patel, PhD, Joins Nanoscope as Senior Vice President of Sales and Marketing [Yahoo! Finance]
Low
Report
Pharmaceutical Industry Veteran, Ashish Patel, PhD, Joins Nanoscope as Senior Vice President of Sales and Marketing [Yahoo! Finance]
3/26
10:31 am
nvs
CAR T-Cell Therapy Market Size To Reach 27.5 Billion by 2033 Owing to Rising Awareness and Favourable Reimbursement Policies Says Astute Analytica [Yahoo! Finance]
Low
Report
CAR T-Cell Therapy Market Size To Reach 27.5 Billion by 2033 Owing to Rising Awareness and Favourable Reimbursement Policies Says Astute Analytica [Yahoo! Finance]
3/25
02:20 am
nvs
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
Low
Report
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
3/21
04:16 pm
nvs
FDA Approves Novartis Drug for Rare Kidney Disease Treatment [Yahoo! Finance]
Low
Report
FDA Approves Novartis Drug for Rare Kidney Disease Treatment [Yahoo! Finance]
3/20
08:08 pm
nvs
Novartis Reports Updated Positive Data From Phase III SMA Program [Yahoo! Finance]
Low
Report
Novartis Reports Updated Positive Data From Phase III SMA Program [Yahoo! Finance]
3/20
08:08 pm
nvs
Novartis builds case for new SMA gene therapy [Yahoo! Finance]
Low
Report
Novartis builds case for new SMA gene therapy [Yahoo! Finance]
3/20
07:37 pm
nvs
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Low
Report
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)